Evidence map›Paper›PMID 33106909›Full record

ArticleAnnals of hematology2021

Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.

Martin Kaiser, Meral Beksaç, Nina Gulbrandsen, Fredrik Schjesvold, Roman Hájek, Philippe Moreau, Felipe de Arriba de la Fuente, María-Victoria Mateos, Sharon West, Andrew Spencer and 7 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Martin KaiserDepartment of Haematology, The Royal Marsden Hospital, London, UK. Martin.Kaiser@icr.ac.uk.
Meral BeksaçDepartment of Hematology, Ankara University, Ankara, Turkey.
Nina GulbrandsenOslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
Fredrik SchjesvoldOslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway.
Roman HájekDepartment of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
Philippe MoreauDepartment of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Felipe de Arriba de la FuenteServicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
María-Victoria MateosDepartment of Hematology, University Hospital of Salamanca, CIC, IBM CC, Salamanca, Spain.
Sharon WestDepartment of Haematology, The Royal Marsden Hospital, London, UK.
Andrew SpencerMalignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia.
S Vincent RajkumarDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Kaveri SuryanarayanMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Michael CzorniakMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Cong LiMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Zhaoyang TengMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Richard LabotkaMillennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
Meletios A DimopoulosHematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33106909
PMCPMC7852957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.